-

Tim Buckley Elected to Pfizer’s Board of Directors

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer’s Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent.

Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard’s Chief Investment Officer, overseeing the company’s internally managed stock, bond and money market portfolios as well as investment research and methodology. Mr. Buckley joined Vanguard in 1991 and held numerous senior leadership roles, including Chief Information Officer and head of the Retail Investor Group. Outside of Vanguard, he served as Chairman of the board of Children’s Hospital of Philadelphia from 2011 to 2017.

Mr. Buckley received a Bachelor of Arts in Economics from Harvard College and a Master of Business Administration from Harvard Business School.

“We are pleased to welcome Tim Buckley to Pfizer’s Board of Directors,” stated Albert Bourla, Pfizer Chairman and Chief Executive Officer. “Tim is a widely respected business leader with deep expertise in global investment management, financial markets, and operations and someone who values a shared sense of purpose, all of which will be an asset to Pfizer and our shareholders.”

“I'm honored to join Pfizer’s Board of Directors, a group of leaders with distinguished careers in science, government, academia, technology and business,” said Buckley. “I'm impressed with Pfizer’s dedication to patients and focus on innovation to improve health. I look forward to working with the Board and management to support the breakthroughs that change patients' lives while concurrently driving long-term shareholder value.”

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Corporate

Contacts

Media Contact:
+1 (212) 733-1226
PfizerMediaRelations@Pfizer.com

Investor Contact:
+1 (212) 733-4848
IR@Pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact:
+1 (212) 733-1226
PfizerMediaRelations@Pfizer.com

Investor Contact:
+1 (212) 733-4848
IR@Pfizer.com

More News From Pfizer Inc.

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.c...

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to app...

Pfizer Declares First-Quarter 2026 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to brin...
Back to Newsroom